Volume 27, Number 12—December 2021
CME ACTIVITY - Synopsis
Clinical Characteristics of Corynebacterium Bacteremia Caused by Different Species, Japan, 2014–2020
, Naoto Hosokawa, Yoshihito Otsuka, and Ryosuke Osawa
Table 2
Clinical diagnosis and characteristics of patients with Corynebacterium species detected in blood culture, Japan, 2014–2020*
| Variable | All, n = 115 | C. striatum, %, n = 67 | C. jeikeium, %, n = 14 | Other species, %, n = 34 | p values |
|
|---|---|---|---|---|---|---|
| C. striatum vs. other species | C. jeikeium vs. other species | |||||
| Age, y |
71 |
71 |
66 |
77 |
0.055 |
<0.001 |
| Sex |
||||||
| M |
80 (70) |
51 (76) |
13 (93) |
16 (47) |
<0.01 |
<0.001 |
| F |
35 (30) |
16 (24) |
1 (7) |
18 (53) |
<0.01 |
<0.001 |
| Underlying disease, no. (%) |
||||||
| Diabetes mellitus |
27 (23) |
14 (20) |
2 (14) |
11 (32) |
0.309 |
0.292 |
| Chronic kidney disease |
16 (14) |
9 (13) |
2 (14) |
5 (15) |
1 |
1 |
| Liver disease |
4 (4) |
4 (6) |
0 (0) |
0 (0) |
0.299 |
NA |
| Solid tumor |
27 (24) |
13 (19) |
4 (29) |
10 (29) |
0.378 |
1 |
| Leukemia† |
20 (17) |
11 (16) |
8 (57) |
1 (3) |
0.056 |
<0.001 |
| Malignant lymphoma‡ |
14 (12) |
8 (12) |
3 (21) |
3 (9) |
0.537 |
0.171 |
| Hematologic malignancy§ |
38 (33) |
24 (36) |
9 (64) |
5 (15) |
0.036 |
<0.01 |
| Underlying condition, no. (%) |
||||||
| Neutropenia, <500 cells/mm3 |
29 (25) |
19 (28) |
8 (57) |
2 (6) |
<0.01 |
<0.001 |
| Corticosteroid |
8 (7) |
5 (8) |
2 (14) |
1 (3) |
0.661 |
0.2 |
| Chemotherapy, within 3 mo |
41 (36) |
23(34) |
10 (71) |
8 (24) |
0.377 |
<0.01 |
| Clinical diagnosis, no. (%) |
||||||
| True bacteremia |
60 (52) |
47 (70) |
10 (71) |
3 (9) |
<0.001 |
<0.001 |
| No focus |
25 (22) |
19 (29) |
6 (43) |
0 |
ND |
ND |
| CRBSI |
17 (15) |
13 (19) |
3 (21) |
1 (3) |
ND |
ND |
| Other focus¶ |
18 (16) |
15 (22) |
1 (7) |
2 (6) |
ND |
ND |
| Contamination | 55 (48) | 20 (30) | 4 (29) | 31 (91) | <0.001 | <0.001 |
*ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; CRBSI: catheter-related blood stream infection; DLBCL, diffuse large B cell lymphoma; MDS, myelodysplastic syndrome; MM, multiple myeloma; NA, not applicable; ND, not done; IVLBCL, intravascular large B cell lymphoma.; PTCL, peripheral T-cell lymphoma.
†No. cases: AML, 17; ALL, 3,
‡No.cases: DLBCL, n = 8: PCTL, n =3; IVLBCL, n = 1; lymphoplasmacytic lymphoma, n= 1,: Burkitt lymphoma, n = 1.
§No. cases: leukemia, n = 20; lymphoma, n = 14; MM, n = 3; MDS, n = 1; myelofibrosis, n = 2.
¶No. cases: pyelonephritis, n = 5; skin and soft tissue infection, n = 4; empyema, n = 2; pneumonia, n = 1; prostatitis, n = 1; infective endocarditis, n = 1; osteomyelitis, n = 1; vascular graft infection, n = 1; central venous port infection, n = 1; spontaneous bacterial peritonitis, n = 1.